Russell Investments Group Ltd. Has $3.76 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Russell Investments Group Ltd. raised its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 50.1% in the first quarter, HoldingsChannel reports. The fund owned 103,822 shares of the biopharmaceutical company’s stock after purchasing an additional 34,635 shares during the quarter. Russell Investments Group Ltd.’s holdings in Ultragenyx Pharmaceutical were worth $3,759,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Deep Track Capital LP acquired a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $27,493,000. First Light Asset Management LLC grew its stake in Ultragenyx Pharmaceutical by 1.1% in the fourth quarter. First Light Asset Management LLC now owns 763,607 shares of the biopharmaceutical company’s stock valued at $32,125,000 after acquiring an additional 8,505 shares during the period. Dark Forest Capital Management LP acquired a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $459,000. Stifel Financial Corp grew its stake in Ultragenyx Pharmaceutical by 13.5% in the fourth quarter. Stifel Financial Corp now owns 23,796 shares of the biopharmaceutical company’s stock valued at $1,001,000 after acquiring an additional 2,835 shares during the period. Finally, Alyeska Investment Group L.P. grew its stake in Ultragenyx Pharmaceutical by 23.1% in the fourth quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company’s stock valued at $60,570,000 after acquiring an additional 269,733 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analysts Set New Price Targets

RARE has been the topic of several analyst reports. HC Wainwright raised Ultragenyx Pharmaceutical to a “buy” rating and set a $80.00 target price on the stock in a research report on Monday, July 28th. Cantor Fitzgerald cut their target price on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 6th. William Blair initiated coverage on Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an “outperform” rating and a $65.00 target price on the stock. Guggenheim reaffirmed a “buy” rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Finally, Canaccord Genuity Group cut their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $81.50.

Ultragenyx Pharmaceutical Trading Up 0.9%

RARE stock opened at $29.78 on Friday. The stock’s fifty day simple moving average is $31.69 and its two-hundred day simple moving average is $35.79. Ultragenyx Pharmaceutical Inc. has a 1-year low of $25.81 and a 1-year high of $60.37. The stock has a market cap of $2.87 billion, a P/E ratio of -5.39 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The business had revenue of $166.50 million for the quarter, compared to analysts’ expectations of $161.37 million. During the same quarter in the previous year, the firm earned ($1.52) earnings per share. The business’s revenue was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insider Activity

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business’s stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the sale, the director directly owned 15,344 shares in the company, valued at $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 5.50% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.